Bic re AMRN. Yes a settlement could come at any time however Dr Reddy in particular is known for not wanting to settle easily as all they risk losing are their attorney fees ...ie AMRN can not claim damages etc if they win .
Addressable market .
Canada is roughly the size of CA ( patient wise ) , EU is larger than US ...re the US ...actual market IMHO is a wide range
1) Strictly those covered by the label including those who are or claim to be statin intolerant .
2) Those that currently take DS alternatives from Costco etc ...around 20m ? ...who will convert to a proven drug for reducing CV risk and get off label scripts for Vascepa
The ICER report estimates that those on Vascepa scripts could be as high as 30 m , 5 yrs from now .
Direct to Consumer ads kick in around mid yr.
Final data from the EVAPORATE trial due by mid year ...hopefully confirming at least slowing the progression of coronary plaque development and possibly halting it .
Direct to consumer ads will play a large part in driving demand as Vascepa is seen as " natural " with a proven benefit .
Vascepa is also very cost effective and will save health providers $ for the on label population ...as per the ICER report ...so expect insurer's to get on board once they accept this.
For now tho ...AMRN is probably trading in a sideways range until the patent challenge ends ...either by settlement or court decision
JMO
Kiwi
Market Data 
Markets 
AI
